|
|
|
 Analyses
Central Europe Pharma News talks to Andrej Pardo, Country Head Czech Republic & Slovakia at Sandoz and the new Chairman of the Association of Pharmaceutical Companies (CAFF) representing generic companies in ... more
»
2012-02-02
The updated version of the Ministry of the Treasury’s privatisation plan for 2009-2011 envisaged the following companies from the pharmaceutical and healthcare sectors to be privatised in the period in question: ... more
»
2012-01-25
In May 2011, the Hungarian government decided to increase the 12% tax payable by pharmaceutical manufacturers on revenues from reimbursed drugs to 20% from 1 July 2011 onwards.
In June 2011, the Hungarian Parliament ... more
»
2012-01-23
The year 2011 saw numerous legislative changes shaking up the Hungarian pharmaceutical market. Pfizer warned that the additional fiscal burden brought about by the new regulations would force innovative pharmaceutical ... more
»
2012-01-23
The online sales of OTC drugs take place in all the Central and Eastern Europe (CEE) countries, but the legal framework in the individual countries imposes specific limitations in this respect. Hence, online sales ... more
»
2012-01-17
Penta, a private-equity group conducting its business on the markets of Central Europe, for 10 last years has been largely active in the healthcare segment in the region, in particular in Slovakia, the Czech Republic ... more
»
2012-01-10
Robust growth and substantial investments are expected in the Romania private healthcare sector. Although the privatisation of hospitals is not imminent, a great deal is happening in the private segment, where several ... more
»
2012-01-10
2011 experienced numerous mergers and acquisitions (M&A) attempts on the pharmaceutical, private healthcare and medical devices markets in Central and Eastern Europe (CEE). The significant consolidation processes took place particularly ... more
»
2012-01-10
The new Reimbursement Act in Poland which is take effect from January 2012 envisages a total ban on sales promotions of reimbursed medicines and on any forms of advertising by pharmacies. However Poland is not the only ... more
»
2011-12-14
This year Hungarian companies Gedeon Richter and Egis improved their positions in the EU’s “2011 Industrial R&D Investment Scoreboard”. This was due to the increased outlays on R&D in 2010. ... more
»
2011-12-14
The 2010-2011 period has seen intensified activity of two Polish companies operating on the domestic in vitro diagnostics market: BioMaxima and PZ Cormay. Both companies have been engaged in the acquisition processes, ... more
»
2011-12-06
Despite the continued pursuit of vigorous cost containment-focused drug sector reform, merger and acquisition activity and foreign direct investment (FDI) remain a major feature of Central and Eastern European (CEE) ... more
»
2011-11-17
Today, pharmaceutical companies are trying to focus resources on core activities and to reduce infrastructure expenses which are not directly related to core functions. They therefore relocate business processes from ... more
»
2011-11-02
In 2010 OTC product pharmacy sales in Central and Eastern Europe (CEE) were worth €10.7bn, a 13% year on year increase in euro. Between 2011 and 2013 the market should develop by around 9% on average per annum, according ... more
»
2011-10-19
Central Europe Pharma News talks to George Commander, CEO of InterHealth Canada, the global healthcare management firm, about its first public-private partnership (PPP) contract in Poland to build, equip and operate ... more
»
2011-10-05
Despite a busy first quarter, with lots of new legislation tabled, the second three months of 2011 witnessed no let up in state efforts to tackle rising public sector drug budgets. At the same time, the region’s ... more
»
2011-09-14
Slovak and Polish patients consume the highest amounts of antibiotics among all the Central and Eastern European (CEE) countries, while Romanians the lowest, according to latest data available from the European ... more
»
2011-09-07
At present, only a few companies based in Central Europe and the Balkans emphasise their contract manufacturing and Active Pharmaceutical Ingredient (API) sourcing services. There is relatively strong competition from ... more
»
2011-08-24
Investment activity started to pick up again on the private healthcare market in Central Europe[1] (CE) in 2010 and 2011. Many companies returned to abandoned projects, and this resulted in new establishments being ... more
»
2011-08-10
see more analytical articles »
|
|
|
Copyright © 2012 PMR. All rights reserved.
PMR is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern Europe as well as other emerging markets. PMR key areas of operation include
business publications (through PMR Publications),
consultancy (through PMR Consulting) and
market research (through PMR Research). Being present on the market since 1995, employing highly skilled staff, offering high international standards in projects and publications, providing one of most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.
PMR Online Access
Browse and search in our archive »